Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type during 2013-2014 in the United States

Journal of Infectious Diseases

Volumn 213, Issue 10, 2016, Pages 1546-1556

  Gaglani, Manjusha ^a   Pruszynski, Jessica ^a   Murthy, Kempapura ^a   Clipper, Lydia ^a   Robertson, Anne ^a   Reis, Michael ^a   Chung, Jessie R ^c,h   Piedra, Pedro A ^b   Avadhanula, Vasanthi ^b   Nowalk, Mary Patricia ^d   Zimmerman, Richard K ^d   Jackson, Michael L ^e   Jackson, Lisa A ^e   Petrie, Joshua G ^f   Ohmit, Suzanne E ^f   Monto, Arnold S ^f   McLean, Huong Q ^g   Belongia, Edward A ^g   Fry, Alicia M ^c   Flannery, Brendan ^c  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^g MARSHFIELD CLINIC   (United States)

^h ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

Author keywords

Influenza; Influenza vaccine; Influenza vaccine effectiveness; Vaccine effectiveness

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; INACTIVATED VACCINE;

2009 H1N1 INFLUENZA; ACUTE RESPIRATORY TRACT DISEASE; ADOLESCENT; CHILD; CONTROLLED STUDY; COUGHING; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; INFLUENZA A VIRUS (H1N1); MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCHOOL CHILD; UNITED STATES; ADULT; AGED; CASE CONTROL STUDY; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; INFANT; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PANDEMICS; SEASON; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; SEASONS; UNITED STATES; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84961737704     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv577     Document Type: Review

References (44)

1. Centers for Disease Control and Prevention (CDC). Update: influenza activity-United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59:901-8.
2. Centers for Disease Control and Prevention (CDC). Update: influenza activity-United States, 2010-11 season, and composition of the 2011-12 influenza vaccine. MMWR Morb Mortal Wkly Rep 2011; 60:705-12.
3. Centers for Disease Control and Prevention (CDC). Update: influenza activity-United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep 2012; 61:414-20.
4. Centers for Disease Control and Prevention (CDC). Influenza activity-United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morb Mortal Wkly Rep 2013; 62:473-9.
5. Epperson S, Blanton L, Kniss K, et al. Influenza activity-United States, 2013-14 season and composition of the 2014-15 influenza vaccines. MMWR Morb Mortal Wkly Rep 2014; 63:483-90.
6. Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014 [published correction appears in MMWR Recomm Rep 2013; 62:906]. MMWR Recomm Rep 2013; 62 (RR-07):1-43.
7. Flannery B, Thaker SN, Clippard J, et al. Interim estimates of 2013-14 seasonal influenza vaccine effectiveness-United States, February 2014. MMWR Morb Mortal Wkly Rep 2014; 63:137-42.
8. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27.
9. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-13: variable protection by age and virus type. J Infect Dis 2015; 211:1529-40.
10. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-9.
11. Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. Vaccine 2015; 33:1313-6.
12. Irving SA, Donahue JG, Shay DK, Ellis-Coyle TL, Belongia EA. Evaluation of selfreported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine 2009; 27:6546-9.
13. Andrews N, Waight P, Yung CF, Miller E. Age-specific effectiveness of an oilin-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011; 203:32-9.
14. Hosmer DW, Lemeshow S. Applied logistic regression. 3rd ed. Hoboken, NJ: John Wiley and Sons, 2013.
15. Griffin MR, Monto AS, Belongia EA, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S.: communities. PLoS One 2011; 6:e23085.
16. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012; 55:951-9.
17. Andrews N, McMenamin J, Durnall H, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill 2014; 19:5-13.
18. Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 2014; 9:e92153.
19. Kissling E, Valenciano M, Buchholz U, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the IMOVE multicentre case-control study, influenza season 2012/13. Euro Surveill 2014; 19:pii: 20701.
20. Yang P, Thompson MG, Ma C, et al. Influenza vaccine effectiveness against medically-attended influenza illness during the 2012-2013 season in Beijing, China. Vaccine 2014; 32:5285-9.
21. Skowronski DM, Janjua NZ, Sabaiduc S, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis 2014; 210:126-37.
22. Levy A, Sullivan SG, Tempone SS, et al. Influenza vaccine effectiveness estimates for Western Australia during a period of vaccine and virus strain stability, 2010 to 2012. Vaccine 2014; 32:6312-8.
23. Skowronski DM, Janjua NZ, De Serres G, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 2012; 55:332-42.
24. Kissling E, Valenciano M, Cohen JM, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One 2011; 6:e27622.
25. Pebody RG, Andrews N, Fleming DM, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiol Infect 2013; 141:620-30.
26. Torner N, Martínez A, Basile L, et al. Influenza vaccine effectiveness assessment through sentinel virological data in three post-pandemic seasons. Hum Vaccin Immunother 2015; 11:225-30.
27. Caspard H, Gaglani M, Clipper L, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. Vaccine 2016; 34:77-82.
28. Cost AA, Hiser MJ, Hu Z, et al. Brief report: mid-season influenza vaccine effectiveness estimates for the 2013-2014 influenza season. MSMR 2014; 21:15-7.
29. Uzicanin A, Thompson M, Smith P, et al. Effectiveness of 1 dose of influenza A(H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in Maine. J Infect Dis 2012; 206:1059-68.
30. Pannaraj PS, Wang HL, Rivas H, et al. School-located influenza vaccination decreases laboratory-confirmed influenza and improves school attendance. Clin Infect Dis 2014; 59:325-32.
31. Kwong JC, Pereira JA, Quach S, et al; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Program Delivery and Evaluation Group. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) cluster randomized trial: Pilot results from a household surveillance study to assess direct and indirect protection from influenza vaccination. Vaccine 2015; 33:4910-5.
32. Skowronski DM, Chambers C, Sabaiduc S, et al. Integrated sentinel surveillance linking genetic, antigenic and epidemiologic monitoring of influenza vaccinevirus relatedness and effectiveness, 2013-14 season. J Infect Dis 2015; 212:726-39.
33. Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011; 29:9391-7.
34. Block SL, Falloon J, Hirschfield JA, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012; 31:745-51.
35. Cotter CR, Jin H, Chen Z. A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS Pathog 2014; 10:e1003831.
36. O'Donnell CD, Vogel L, Matsuoka Y, Jin H, Subbarao K. The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccines. J Virol 2014; 88:12374-84.
37. Forrest BD, PrideMW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008; 15:1042-53.
38. Gaglani M, Spencer S, Ball S, et al. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis 2014; 209:1705-14.
39. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 2014; 59:1375-85.
40. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children [published correction appears in N Engl J Med 2007; 356:1283]. N Engl J Med 2007; 356:685-96.
41. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-9.
42. Ashkenazi S, Vertruyen A, Arístegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-9.
43. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 2014; 63:691-7.
44. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) reaffirms recommendation for annual influenza vaccination. http://www.cdc.gov/media/releases/2015/s0226-acip.html. Accessed 13 April 2015.